CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 290 enrolled
Drug / intervention
IncobotulinumtoxinA (400 Units) +1 moredrug
Likely dose
IncobotulinumtoxinA (400 Units)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01464307
NCT01464307Phase 3Completed

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb

Merz Pharmaceuticals GmbH·interventional·Posted Nov 3, 2011·Updated Nov 7, 2016

In Brief

A Phase 3 clinical trial evaluating IncobotulinumtoxinA (400 Units) and Placebo Comparator for Post-stroke Spasticity of the Lower Limb. Completed, enrolled 290 participants across 53 sites in 9 countries.

Detailed Summary

The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg are effective in treating patients with increased muscle tension/uncontrollable muscle stiffness (spasticity) after a stroke.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Czechia, France, Germany, Italy, Poland, Russia, Spain, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 3, 2011
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.7 years ago

Interventions

IncobotulinumtoxinA (400 Units)drug

Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.

Placebo Comparatordrug

Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection